COVID-19 in multiple sclerosis: The Dutch experience

Area of Science:

• Neurology
• Infectious Diseases
• Immunology

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• The impact of COVID-19 on MS patients requires thorough investigation, especially concerning treatment and disease severity.
• Understanding COVID-19 outcomes in MS patients is crucial for clinical management and patient care.

Purpose of the Study:

• To analyze COVID-19 cases in multiple sclerosis patients in the Netherlands.
• To evaluate the relationship between disease-modifying treatment (DMT) use and COVID-19 disease course in MS patients.
• To determine if low lymphocyte count is associated with severe COVID-19 in this population.

Main Methods:

• Data collected by the Dutch MS Taskforce of the Netherlands Society of Neurology.
• Inclusion of all reported COVID-19 cases in MS patients between February 27 and June 9, 2020.
• Analysis of patient demographics, COVID-19 status, hospitalization, ICU admission, mortality, DMT use, and lymphocyte counts.

Main Results:

• A total of 86 MS patients were reported; 43 tested positive for COVID-19.
• Of those positive, 22 were hospitalized, with 3 ICU admissions and 4 deaths.
• No significant difference in COVID-19 disease course was observed based on DMT use.
• A clear link between low lymphocyte count and severe COVID-19 disease was not identified.

Conclusions:

• COVID-19 outcomes in Dutch MS patients did not appear to be significantly influenced by disease-modifying treatment.
• Low lymphocyte count was not found to be a reliable indicator of severe COVID-19 in this cohort of MS patients.
• Further research may be needed to fully elucidate the complex interactions between MS, its treatments, and viral infections like COVID-19.